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Abstract: Tricyclic antidepressants (TCAs) are among the most effective antidepressants avail-
able, although their poor tolerance at usual recommended doses and toxicity in   overdose make 
them difficult to use. While selective serotonin reuptake inhibitors (SSRIs) are   better tolerated 
than TCAs, they have their own specific problems, such as the aggravation of sexual dysfunc-
tion, interaction with coadministered drugs, and for many, a discontinuation syndrome. In addi-
tion, some of them appear to be less effective than TCAs in more severely depressed patients. 
Increasing evidence of the importance of norepinephrine in the etiology of depression has led 
to the development of a new generation of antidepressants, the serotonin and   norepinephrine 
reuptake inhibitors (SNRIs). Milnacipran, one of the pioneer SNRIs, was designed from theo-
retic considerations to be more effective than SSRIs and better tolerated than TCAs, and with a 
simple pharmacokinetic profile. Milnacipran has the most balanced potency ratio for reuptake 
inhibition of the two neurotransmitters compared with other SNRIs (1:1.6 for milnacipran, 1:10 
for duloxetine, and 1:30 for venlafaxine), and in some studies milnacipran has been shown to 
inhibit norepinephrine uptake with greater potency than serotonin (2.2:1). Clinical studies have 
shown that milnacipran has efficacy comparable with the TCAs and is superior to SSRIs in severe 
depression. In addition, milnacipran is well tolerated, with a low potential for pharmacokinetic 
drug–drug interactions. Milnacipran is a first-line therapy suitable for most depressed patients. 
It is frequently successful when other treatments fail for reasons of efficacy or tolerability.
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Introduction
Depression is characterized by the presence of two core symptoms, depressed mood 
and anhedonia (decreased pleasure or interest). It is also accompanied, however, by a 
plethora of other signs and symptoms, such as changes in appetite and sleeping, fatigue 
and loss of energy, psychomotor agitation or retardation, feelings of worthlessness or 
inappropriate guilt, diminished ability to think or concentrate, and recurrent thoughts 
of death or suicide.1 A relationship exists between the monoamine neurotransmitters 
in the brain, norepinephrine (NE) and serotonin (5-hydroxytryptamine, 5-HT) and the 
symptoms of major depressive disorder (Figure 1).2 Specific symptoms are thought 
to be associated with the increase or decrease of specific monoamines, implying the 
involvement of specific neurochemical mechanisms.
Virtually all antidepressants increase the synaptic concentrations of 5-HT and/or 
NE by blocking the reuptake of one or both of these neurotransmitters. The archetypal 
tricyclic antidepressants (TCAs) block NE and 5-HT transporters to a varying extent 





antidepressants available,4 their poor tolerance and toxicity 
in overdose due to the   involvement of other neurotransmitter 
systems make them difficult to use at effective doses.5 The 
principal side effects of the TCAs are considered to be due 
essentially to their relatively high affinity for α1-adrenergic 
receptors, H1-  histamine receptors, and muscarinic cholin-
ergic receptors.6 The selective serotonin reuptake inhibitors 
(SSRIs) which inhibit selectively the single neurotransmitter, 
5-HT, are effective   antidepressants. Although they have no 
  affinity for α1-adrenergic receptors, H1-histamine receptors, 
and muscarinic cholinergic receptors, and are better tolerated 
than TCAs,6 they have their own specific problems, such as 
aggravation of sexual dysfunction, interaction with coadmin-
istered drugs and, for many, a discontinuation syndrome.7 In 
addition, some of them appear to be less effective than TCAs, 
with a number needed to treat for TCAs of about four com-
pared with six for SSRIs in primary care.8 The difference is 
most pronounced in more severely depressed patients.9
In general, antidepressants achieve a response ($50% 
reduction in baseline depression score) in less than 70% 
of patients and remission (a complete absence of depres-
sive symptoms) in less than 50%. Increasing evidence of 
the importance of NE in the etiology of depression10 and 
the idea that “two actions are better than one” have led to 
the development of a new class of compounds that block the 
reuptake of both 5-HT and NE without the nonspecific, side 
effect-inducing receptor interactions of TCAs. This class, 
the serotonin (5-HT) and NE reuptake inhibitors (SNRIs) 
comprises venlafaxine (and its active metabolite, desvenla-
faxine), duloxetine, and milnacipran.11
By definition, the SNRIs inhibit both 5-HT and NE 
transporters. There is, however, considerable difference 
in their selectivity for the two transporters (Table 1 and 
Figure 2). Venlafaxine has a much greater affinity for 
the 5-HT transporter than for the NE transporter. At low 
doses, it probably inhibits almost exclusively the 5-HT 
transporter, acting like a SSRI, with significant NE reuptake 
inhibition only occurring at higher doses. Duloxetine has 
a more balanced affinity, but is still more selective for the 
5-HT transporter. Milnacipran is the most balanced SNRI, 
and some studies have even found it to be slightly more 
Table 1 inhibition of binding to human monoamine transporters 
in vitro
Potency ratio Ki (nM) Selectivity
5-HT NE NE/5-HT
Milnacipran 123 200 1/1.6
Duloxetine 0.8 7.5 1/9
venlafaxine 82 2483 1/30
Desvenlafaxine 40 558 1/14
Milnacipran, duloxetine and venlafaxine data from Koch et al55 and desvenlafaxine 
data from Deecher et al.56
























Figure 1 relation between neurotransmitters and symptoms of depression.
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effective for the NE transporter12 compared with the 5-HT 
transporter.
There is frequently confusion between the terms “selec-
tivity” and “potency”, which refer to two different entities. 
Potency reflects the concentration of the antidepressant inhib-
iting 50% of uptake or binding to the transporter, depending 
on the technique used. Thus from Table 1 it can be seen that 
duloxetine is 154 times more potent than milnacipran at 
blocking the binding of 5-HT to the transporter (ie, 154 times 
more milnacipran is required to obtain the same effect). 
To block the binding of NE to its transporter, duloxetine is 
about 27 times more potent than milnacipran. If absorption, 
metabolism, distribution, brain penetration and distribution, 
and elimination were identical for the two drugs, it would be 
necessary to give 154 times more milnacipran than duloxetine 
to achieve the same effect on 5-HT reuptake and 27 times 
more milnacipran to have the same effect on NE reuptake. 
Of course the kinetic parameters vary considerably between 
these two compounds, and certain parameters are impossible 
to determine in humans (eg, brain penetration) and hence this 
calculation remains purely theoretical.
The selectivity of an antidepressant is the ratio of 
the potency values for NE and 5-HT reuptake inhibition 
(or inhibition of binding to the transporter). As shown in 
Table 1, milnacipran has a selectivity close to 1, duloxetine 
close to 10 (in favor of 5-HT), and venlafaxine close to 
30. Thus, in a dose titration, when milnacipran starts to 
inhibit 5-HT reuptake, it also starts to inhibit NE reuptake; 
when it inhibits 5-HT reuptake by 50%, it also inhibits NE 
reuptake by approximately 50%, and so on. Increasing the 
dose does not alter the “nature” of the effect. At all doses 
it has an equivalent effect on the two neurotransmitters 
systems. In contrast, a dose titration with venlafaxine will 
give (eg, at 75 mg) an initial inhibition of 5-HT reuptake 
with no inhibition of NE uptake. Only at much higher doses 
(eg, 200–250 mg) is there any significant inhibition of NE 
reuptake, but at this dose the inhibition of 5-HT reuptake 
is already 100%. Thus, titrating venlafaxine changes the 
“nature” of its effect from a SSRI to a SNRI as the dose 
is increased. The situation with duloxetine is intermediate 
between milnacipran and venlafaxine.
There are some indications that the mechanism of 
  milnacipran may be more complex than a simple action at 
the monoamine transporter, and thus is different from the 
other SNRIs. A study assessed the effect of milnacipran on 
the firing activity of dorsal raphe 5-HT neurons and locus 
coeruleus NE neurons using extracellular unitary recording in 
rats.13 The authors concluded that milnacipran had profound 
effects on the function of 5-HT and NE neurons, but that the 
mechanism by which 5-HT neurons regained their normal 
firing during milnacipran treatment appears to implicate the 
NE system.
In a more recent study,14 duloxetine and venlafaxine 
were found to increase 5-HT levels in the brainstem and 
5-HT terminal areas, whereas milnacipran increased 5-HT 
levels only in the brainstem. Significant reductions in 5-HT 
turnover were observed in various forebrain regions, includ-
ing the hippocampus and hypothalamus, after treatment 
with duloxetine or venlafaxine, but not after milnacipran. In 
addition, venlafaxine and duloxetine significantly increased 
dopamine (DA) levels and decreased DA turnover in the 
nucleus accumbens, whereas milnacipran only increased DA 
levels in the medial prefrontal cortex. The authors concluded 
that the effects of milnacipran were unique because it caused 
increases in DA in the medial prefrontal cortex and in 5-HT 
in the midbrain without any changes in monoamine turnover. 
They suggested that milnacipran might exert its therapeutic 
effects by activating the dopaminergic system in the medial 
prefrontal cortex, and that milnacipran was in this respect 










Figure 2 Selectivity of different serotonin and norepinephrine reuptake inhibitors for the monoamine transporters. The segments represent the selectivity for the human 





Some notable characteristics  
of milnacipran
In addition to its balanced action on the two monoamine 
transporters, preclinical and clinical studies have shown 
that milnacipran possesses certain characteristics which are 
relatively unusual in an antidepressant.
Milnacipran has no active metabolites. Unlike the 
  majority of antidepressants, milnacipran is only metabolized 
to a very minor extent, with most of the administered drug 
being excreted in the urine either unchanged or as the inactive 
glucurono-conjugate.15 Whereas most antidepressants   interact 
with cytochrome P450 enzymes as inhibitors, inducers, or 
substrates,16 milnacipran has been shown to be essentially 
devoid of interactions with any cytochrome P450 enzyme.17 
In addition, milnacipran binds to only a very limited extent 
(13%) to serum albumin.15 Milnacipran, therefore, has a low 
risk of pharmacokinetic drug-drug interactions.
Depression is associated with sexual disturbances, 
  including decreased libido, anorgasmia, and erectile   problems. 
Since introduction of the SSRIs, it has become apparent that 
aggravation of sexual dysfunction is a frequent problem 
for patients taking these drugs, with some studies reporting 
rates as high as 75%.18 Sexual dysfunction caused by SSRIs 
is related to stimulation of 5-HT2 and 5-HT3 receptors but 
its origin is complex and probably involves other systems 
as well.19 Venlafaxine20 and duloxetine21,22 also exacerbate 
sexual dysfunction at frequencies similar to those seen with 
SSRIs. A study using the Sexual Function and Enjoyment 
Questionnaire 23 showed no aggravation of sexual disturbance 
with milnacipran, which improved sexual function in parallel 
with improvement in other symptoms of depression.
Following abrupt discontinuation, most SSRIs, and 
  paroxetine in particular, produce a number of adverse events, 
including dizziness, nausea, headache, paresthesia, vomiting, 
irritability, and nightmares.24 Venlafaxine and duloxetine 
produce similar discontinuation emergent adverse events.25,26 
A post hoc analysis of patients abruptly withdrawn from 
  paroxetine or milnacipran as part of a double-blind comparative 
study27 showed that paroxetine produced significantly more 
discontinuation emergent adverse events than milnacipran. In 
addition, the nature of the adverse events differed between the 
two antidepressants, with patients withdrawn from paroxetine 
showing the classical symptoms of dizziness, anxiety, and sleep 
disturbance (insomnia and nightmares), while those withdrawn 
from milnacipran showed only increased anxiety. However, 
some discontinuation symptoms have been reported, and good 
clinical practice and regulatory authorities always recommend 
gradual discontinuation from any psychotropic drug.
Certain antidepressants are associated with clinically 
significant weight changes. In particular, some TCAs includ-
ing amitriptyline, certain SSRIs including paroxetine, and 
other antidepressants, such as mirtazapine, are frequently 
associated with significant weight gain.28 Data from a wide 
range of clinical trials29 have shown that 82% of patients 
taking milnacipran 100 mg/day for 3 months or more have 
no clinically significant weight change (defined as .5% 
of body weight). Of the remainder, 10% had clinically 
significant weight loss, while 8% had clinically significant 
weight gain.
Comparison of milnacipran  
with TCAs and SSRIs
Seven randomized, double-blind trials with similar designs 
have compared the efficacy and tolerability of milnacipran 
and TCAs in patients with major depression. At a dose of 
100 mg/day the response rate with milnacipran (64%) was 
comparable with that of the TCAs (67%). In contrast with the 
TCAs, milnacipran was very well tolerated by patients.30
A meta-analysis of studies comparing milnacipran at 
100 mg/day with the SSRIs, fluvoxamine (200 mg/day) and 
fluoxetine (20 mg/day), in moderately to severely depressed 
hospitalized patients,31 reported significantly more respond-
ers (64%) with milnacipran than with the two SSRIs (50%, 
P , 0.01) and a significantly higher remission rate (38.7% 
versus 27.6%, P , 0.04). Another study, published subsequent 
to this meta-analysis, compared milnacipran with paroxetine 
20 mg/day in less severely depressed outpatients, and reported 
similar remission rates for the two antidepressants.32
Table 2 summarizes two studies, each comparing 
milnacipran with a SSRI, one in moderately to severely 
depressed hospitalized patients,33 and the other in less severely 
depressed outpatients.34 The two studies, which investigated 
two different SSRIs in different treatment settings, cannot be 
Table 2 Efficacy of milnacipran compared with SSRIs: comparison 
of two studies in mild-to-moderate and severe depression
Mean MADRS scores
Mild-moderate32 Severe33
Miln SSRI1 Miln SSRI2
Baseline 28.9 29.6 37.1  35.5 
endpoint 13.6§ 12.8§ 12.9§,*  18.1§ 
∆ score (endpoint – baseline)  15.3 16.8 24.2* 17.4
Notes: 1paroxetine 20 mg/day; 2fluvoxamine 200 mg/day; §P , 0.05 compared with 
the corresponding baseline value; *P , 0.05 compared with the corresponding value 
for the SSri group. 
Abbreviations:  MADrS,  montgomery  asberg  depression  rating  scale;  miln, 
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compared directly. Nevertheless, it is interesting to note that 
milnacipran was associated with significant improvement in 
both studies. In contrast, the SSRIs led to an improvement 
comparable with that of milnacipran in the study of less 
severely depressed patients, but not in the study of patients 
with severe depression. Unlike milnacipran, SSRI treatment 
did not achieve the additional reduction in depression score 
needed in the severely depressed patients to reach response. 
Clearly this analysis is only indicative and the severity of 
depression was not the only factor that differed between the 
studies. Nevertheless, the results are compatible with other 
data34 suggesting that SSRIs may have a limited capacity 
for improving depressive symptoms, which becomes more 
evident in more severely depressed patients.
In the study comparing milnacipran with paroxetine 
20 mg/day,32 the overall efficacy of the two antidepres-
sants was similar. However, milnacipran was significantly 
better than paroxetine in the subgroup of patients scoring 
maximally at baseline on the retardation-slowness of thought 
and speech, impaired ability to concentrate, and decreased 
motor activity factor (item 8) on the Hamilton Depression 
Rating Scale (HDRS, Figure 3). This is compatible with the 
finding that reduced noradrenergic neuronal tone is related 
to psychomotor retardation.35 Furthermore, the selective NE 
reuptake inhibitor has been shown to improve psychomotor 
retardation systematically, even when other symptoms were 
not improved.36 These data suggest that depressed patients 
with marked psychomotor retardation may benefit particu-
larly from treatment with milnacipran.
In studies comparing milnacipran with SSRIs, both 
compounds are generally well tolerated. The most frequent 
adverse event with both milnacipran and SSRIs is nausea, 
although this occurred less frequently with milnacipran.31 As 
would be expected, adverse effects that are probably related 
to noradrenergic stimulation, such as dry mouth, sweating, 
and constipation, occur more frequently with milnacipran 
than with SSRIs, although the differences are not as large as 
might be expected.31
A meta-analysis of all published studies   comparing 
  milnacipran with SSRIs37 concluded that patients on 
  milnacipran had the same probability of obtaining a clinical 
response as those on SSRIs. As with many meta-analyses, 
however, this global analysis grouped certain atypical studies 
which should have been analyzed separately. For example, 
one study38 comparing milnacipran with fluoxetine used 






























Figure 3 Antidepressant response and psychomotor retardation. retardation score was the score of item 8 on the Hamilton Depression rating Scale (slowness of thought 
and speech, impaired ability to concentrate, decreased motor activity). Dark grey columns = milnacipran; light grey columns = paroxetine. Figure drawn from data in Sechter 





of the half-life of milnacipran (7–8 hours) this protocol was 
inappropriate given that twice daily dosing of milnacipran 
is recommended. In two studies,39,40 each comparing two 
doses of milnacipran with a single dose of a SSRI, the meta-
analysis inappropriately compared each dose of milnacipran 
with the SSRI, using the single SSRI group twice, thus giving 
excessive importance to the SSRI groups. Most importantly, 
however, the analysis combined, without distinction, data 
from a study in severely depressed hospitalized patients33 
(baseline HDRS . 32) with data from studies in mildly 
depressed outpatients32,41 (baseline HDRS , 24).
Another analysis of studies comparing milnacipran with 
SSRIs42 concluded that, on the basis of all available evidence, 
milnacipran, like duloxetine and mirtazapine, had “probable 
superior efficacy” compared with SSRIs.
Comparison of milnacipran  
with other SNRIs
With the exception of the study described in this supple-
ment43 which showed equivalent efficacy of milnacipran and 
venlafaxine at high doses, no studies comparing milnacipran 
with other SNRIs have been carried out. However, all three 
SNRIs have been compared with SSRIs, and comparisons 
of venlafaxine with SSRIs and milnacipran with SSRIs have 
been subjected to meta-analyses which have been juxtaposed 
for comparison.11 A similar level of efficacy for the SSRIs 
was seen across all of the studies. Milnacipran, as well as 
venlafaxine, produced remission rates about 10% higher 
than those of the SSRIs.11 More recently a meta-analysis of 
93 trials comparing a dual-action antidepressant (venlafaxine, 
milnacipran, duloxetine, mirtazapine, mianserin, or moclo-
bemide) with one or more SSRIs has been published.44 This 
analysis, involving over 17,000 patients, confirms the overall 
superiority of the dual-action antidepressants compared with 
the SSRIs (Figure 4). In addition, this meta-analysis shows 
a similar level of efficacy for all of the dual-action antide-
pressants, with the exception of duloxetine which, in this 
analysis, was less effective than the other dual-acting agents. 
Thus, it would seem reasonable to conclude that there is a 
comparable level of antidepressant efficacy for milnacipran 
and venlafaxine and probably duloxetine, although further 
data is required for the latter.
Similarly, in the absence of direct comparative stud-
ies between the SNRIs it is not possible to draw any firm 
conclusions on comparative tolerability. However, in the 
various studies comparing an SNRI with SSRIs, the side 
effect profiles of all three SNRIs show qualitative differences 
in comparison with those of the SSRIs. The most common 
adverse effects with the SSRIs are nausea, vertigo/dizziness, 
dry mouth, and insomnia. Only dry mouth appears to be 
0.80












































Figure 4 Meta-analysis of 93 studies comparing dual action antidepressants and selective serotonin reuptake inhibitorsinvolving 17,036 patients.37 Columns show the relative 
probability of response compared with selective serotonin reuptake inhibitors. Figure drawn from data in Papakostas et al.44
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systematically more common with SNRIs than with SSRIs. 
The dry mouth experienced with SNRIs is of noradrenergic 
origin and is analogous to that encountered during stress. The 
overall frequency of adverse events with milnacipran appears 
to be less than for venlafaxine and duloxetine.11 However, 
direct head-to-head comparisons are needed before any firm 
conclusions can be drawn.
Fatalities have been reported due to overdose of venlafax-
ine alone or in combination with other compounds,45,46 often 
following serotonin syndrome. Fatal toxicity index (deaths 
caused by a drug/million prescriptions) is a very crude mea-
sure of drug toxicity and should be interpreted with caution. 
Nevertheless, fatal toxicity studies from England, Scotland, 
and Wales have provided some interesting data. Deaths due 
to acute poisoning by a single antidepressant have been com-
piled for the period 1993–1999.47 While the SSRIs caused 
between 1–3 deaths/million prescriptions, venlafaxine had an 
index of over 13 deaths/million   prescriptions. A   subsequent 
analysis for the period 1998–2000 found similar results (1–3 
and 13 deaths/million prescriptions, for SSRIs and venlafax-
ine, respectively).48
Milnacipran appears not to cause any particular concern 
in overdose. Patients have absorbed up to 2.8 g (one month’s 
supply at the recommended dose) without any major effects 
other than sedation. In particular, no cardiovascular complica-
tions have been recorded. No fatalities have been recorded 
with milnacipran alone.49 At the present time, no cases of 
lethal overdose with duloxetine have been published.
Efficacy of milnacipran in preventing 
recurrent depressive episodes
Major depression is generally a recurrent disorder and 
75%–80% of patients experience repeated episodes.50 There 
is also evidence that the risk of recurrence tends to increase 
with each successive episode.50,51 The role of an efficient 
antidepressant is therefore not only to get patients well, but 
to keep them well.
A recurrence prevention study with milnacipran consisted 
of a six-week open treatment period followed by a continu-
ation phase of 18 weeks for the responders. Patients with a 
sustained remission at the end of this 24-week period were 
randomized to continuing treatment with milnacipran or to 
placebo under double-blind conditions and followed for a 
further 12 months. There was significantly less recurrence 
of depressive episodes in milnacipran-treated patients, as 
determined by Kaplan-Meier analysis of the cumulative prob-
ability of recurrence.52 By the end of the 12-month double-
blind phase, 16.3% of patients treated with milnacipran 
had relapsed compared with 23.6% of patients on placebo 
(P , 0.05). The level of tolerability and safety of milnacipran 
during this 18-month study was equivalent to that reported in 
relapse/recurrence prevention studies with SSRIs.53,54
Milnacipran: a unique 
antidepressant?
Whether or not the profile described above justify referring 
to milnacipran as a unique antidepressant, it is clear that this 
agent has a distinct combination of characteristics.
It is the only SNRI with a balanced (1:1) activity on NE 
and 5-HT reuptake inhibition. Its efficacy in mild,   moderate, 
and severe depression and a good overall tolerability are 
  combined with a low risk of causing pharmacokinetic 
  drug-drug interactions, sexual dysfunction, minimal effects 
on body weight in normal-weight patients, and a lack of 
toxicity in overdose. This particular profile qualifies mil-
nacipran as a first-line antidepressant for many depressed 
patients. Milnacipran may be particularly well-suited for 
low-energy, slowed-down patients. Patients who have been 
withdrawn from SSRIs or other antidepressants due to lack 
of efficacy or intolerance may find milnacipran to be an 
effective therapeutic option.
Note that this overview highlights what we consider to 
be the most interesting and relevant points of the profile of 
milnacipran and does not claim to be exhaustive. Approved 
indications and safety recommendations may vary between 
countries, so prescribers should check on the summary of 
product characteristics in their own country.
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